Skip to main content

A Phase 1b Study Evaluating the Safety, Tolerability and Preliminary Anti-tumor Activity of NT-I7 (efineptakin alfa) a Long-acting Human IL-7, post-Tisagenlecleucel (Kymriah®) in Subjects with Relapsed/Refractory Large B-cell Lymphoma

Clinical Trial Grant
Duke Scholars

Administered By

Duke Cancer Institute

Awarded By

NeoImmuneTech, Inc.

Start Date

September 28, 2021

End Date

October 31, 2026
 

Administered By

Duke Cancer Institute

Awarded By

NeoImmuneTech, Inc.

Start Date

September 28, 2021

End Date

October 31, 2026